Ismigen tablets 7mg, No. 30

Acute and subacute infections of the upper and lower respiratory tract, including complications after influenza (treatment in combination therapy): bronchitis; tonsillitis; pharyngitis; laryngitis; rhinitis; sinusitis; otitis.

Recurrent infections of the upper and lower respiratory tract, chronic bronchitis (prevention of exacerbations).

Under the tongue; take on an empty stomach. The tablet should be kept under the tongue until it is completely dissolved. Sublingual tablets should not be sucked, chewed or swallowed.

Acute and subacute upper and lower respiratory tract infections

1 tablet / day until the symptoms of the disease disappear (at least 10 days).

Recurrent infections of the upper and lower respiratory tract, prevention of exacerbations of chronic respiratory diseases

1 tablet / day for 10 days.

The preventive course includes three cycles of 10 days with 20-day intervals between them. The prophylactic course should be carried out no more than 1-2 times a year. If you skip taking the next dose, you should not double it the next time you take it. If after treatment there is no improvement or the symptoms worsen, or new symptoms appear, the patient should consult a doctor.

bacterial lysates (Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae (types - TY1 ??/ EQ11, TY2 / EQ22, TY3 / EQ14, TY5 / EQ15, TY8 / EQ23, TY47 / EQ24), Kelebsiella influenza pneumonia b, Neisseria catarrhalis) * 7mg

* in the form of lyophilized bacterial lysates - 50 mg. Excipient: glycine - 43 mg.

• hypersensitivity to active and / or auxiliary components of the drug;

• autoimmune diseases;

• pregnancy;

• breastfeeding period;

• children under 3 years old

pharmachologic effect

Combined immunostimulating drug of bacterial origin for sublingual (sublingual) administration. It is a polyvalent antigenic complex containing lysates of bacteria - the most common causative agents of respiratory infections. The lysates that make up IsmigenЃ are obtained by mechanical destruction of bacterial cells. IsmigenЃ has a nonspecific immunostimulating and specific vaccination effect. IsmigenЃ sublingual tablets have an effect on various links of the immune system. Stimulates both local (increases the concentration of secretory IgA) and systemic (cellular and humoral) immunity. Activates phagocytosis, increases the content of lysozyme in saliva, increases the number of immunocompetent cells, increases the concentration of serum IgA, IgG,IgM and reduces the concentration of serum IgE. Increases the functional and metabolic activity of macrophages (including alveolar) and polymorphonuclear leukocytes, which contributes to the destruction of infectious agents. As a result of treatment with IsmigenЃ, the frequency, severity and duration of acute infections of the respiratory tract are reduced; relief and leveling of symptoms such as fever, cough, shortness of breath is observed, the need for antibacterial and anti-inflammatory therapy decreases; in patients with chronic diseases of the respiratory tract, the drug also prevents exacerbations.As a result of treatment with IsmigenЃ, the frequency, severity and duration of acute infections of the respiratory tract are reduced; relief and leveling of symptoms such as fever, cough, shortness of breath is observed, the need for antibacterial and anti-inflammatory therapy decreases; in patients with chronic diseases of the respiratory tract, the drug also prevents exacerbations.As a result of treatment with IsmigenЃ, the frequency, severity and duration of acute infections of the respiratory tract are reduced; relief and leveling of symptoms such as fever, cough, shortness of breath is observed, the need for antibacterial and anti-inflammatory therapy decreases; in patients with chronic diseases of the respiratory tract, the drug also prevents exacerbations.

Side effect

The incidence of side effects is classified according to the WHO recommendations: very often (more than 10%); often (more than 1 and less than 10%); infrequently (more than 0.1 and less than 1%); rarely (more than 0.01 and less than 0.1%); very rare (less than 0.01%), the frequency is unknown (cannot be determined from the available data). Skin and subcutaneous tissue disorders: very rarely - urticaria, dermatitis, folliculitis; frequency unknown - allergic reactions such as rash, itching and angioedema. Others: very rarely - inflammation of the salivary gland, acute laryngitis, rhinitis. If the above side effects are noted or aggravated, or other side effects occur, the patient should inform the doctor about it.

Application during pregnancy and lactation

Use during pregnancy and breastfeeding is contraindicated.

Application in children

The use of the drug is contraindicated in children under the age of 3 years. Children aged 3 to 6 years, while taking it every day, until the tablet is completely dissolved in the mouth, should be supervised by adults.

special instructions

Children aged 3 to 6 years, while taking it every day, until the tablet is completely dissolved in the mouth, should be supervised by adults.

Influence on the ability to drive vehicles and mechanisms

Does not affect the ability to drive vehicles, mechanisms and to engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Overdose

There are no data on cases of overdose.

Drug interactions

IsmigenЃ can be used concurrently with other drugs intended for the treatment of acute and chronic respiratory diseases. The features of the interaction of IsmigenЃ with other drugs have not yet been described. If the patient is taking the above or other medications (including over-the-counter), he should consult a doctor